Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 7Withdrawn 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 2Multiple Myeloma 2Hodgkin Disease 2Stomatitis 1Recurrence 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Mucositis 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 4Whole-Body Irradiation 3Rituximab 3Etoposide 3Cytarabine 3Carmustine 3Therapeutics 2Tacrolimus 2Saline Solution 2Radiotherapy 2Polymerase Chain Reaction 2Pentetic Acid 2O(6)-benzylguanine 2Methotrexate 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Fibroblast Growth Factor 7 2Dexamethasone 2Busulfan 2sargramostim 1romidepsin 1plerixafor 1pembrolizumab 1merphos 1fludarabine 1ferric pyrophosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Hodgkin Disease × Fibroblast Growth Factor 7 × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00570999 2012-05-10

KGF Haplo Allo

European Society for Blood and Marrow Transplantation

Phase 2 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡